Skip to content

Rapid effect of Flutiform on pulmonary function compared with Relvar and Symbicort

Rapid effect of Flutiform on pulmonary function compared with Relvar and Symbicort - Rapid effect of Flutiform on pulmonary function compared with Relvar and Symbicort

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000029379
Enrollment
15
Registered
2017-10-02
Start date
2017-10-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Single dose of Flutiform 125 Aerosol 2 puffs Single dose of Symbicort Turbohaler 2 inhalations Single dose of Relvar Ellipta single inhalationt

Sponsors

Tohno Chuo Clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: <Visit 0> (1) Patients who were diagnosed as bronchial asthma. (2) Men or women aged >=20 and <80 years on the date of consent. (3) Patients who are able to change ICS/LABA to ICS with same titer. (4) Patients who are able to visit in the morning. (5) Patients who can voluntary provide consent with sufficient understanding of participation. <Visit 1> (1) Patients who provide consent based on the informed consent document. (2) Patients whose severity of asthma were mild persistent or moderate persistent by JGL2015. (3) Patients who were step 2 or 3 by JGL2015. (4) Patients' symptoms in current treatment are "Controlled" or "Mild intermittent". (5) ACQ <= 0.75. (6) No asthma exacerbation during three months.

Exclusion criteria

Exclusion criteria: <Visit 1> (1) Obvious COPD, ACO. (2) >=10 pack-years. (3) Patients who are not able to operate inhaler device. (4) Patients who used ICS/LABA or changed the dose of ICS during Run-in period. (5) Patients who inhaled Flutide Diskus before visit. (6) Chronic airway infection. (7) Patients who are complicated with severe liver, kidney and heart disease. (8) Patients who merger malignant tumor. (9) Patients who are pregnant or are likely to be pregnant. (10) Patients who are inadequate as the study subjects.

Design outcomes

Primary

MeasureTime frame
Mean change of FEV1 from pre-dose FEV1 (3 minutes after inhalation)

Secondary

MeasureTime frame
1) Pulmonary function parameters Measured value at each evaluation point -Amount of change, change rate from pre-dose -AUC (change of amount from pre-dose) 2) Asthma control level -ACQ score -JACS score -Correlation between JACS and ACQ 3) Adverse Events

Countries

Japan

Contacts

Public ContactHiroyuki Ohbayashi

Tohno Chuo Clinic Respiratory medicine

aims_reserve@yahoo.co.jp0572-67-1118

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026